House
GuidelinesCalculatorsPricingBlog
Ask House ↗
Guidelines↗Calculators↗Pricing↗Blog↗
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House
Back to guidelines
Ophthalmology

Dry eye syndrome

AAO · 2024 edition / updateSource checked 29 October 2026
Read the source publication
House clinical summary

Scope

The AAO Preferred Practice Pattern treats dry eye as a multifactorial ocular-surface disorder requiring clinical assessment, correction of contributing factors and long-term individualized care. This selected summary covers diagnosis, staged treatment, surgical precautions and referral. Aqueous deficiency and evaporative disease frequently coexist; symptoms and examination findings may not correlate closely.

Written by House with AI assistance · AI-assisted source check 29 October 2026.

This is House’s summary of the cited guidance. The source check is not an independent clinician review. Open the publication for complete recommendations, exceptions, evidence grades and later amendments.

Establish the diagnosis and contributing mechanisms

  • Use clinical examination to diagnose dry eye and distinguish other causes of irritation or redness. No single diagnostic test is sufficient; combine history, examination and relevant tests rather than diagnosing from one result. [1]
  • Assess symptoms, duration, environmental triggers and prolonged visual tasks. Review topical medicines and preservatives, contact lenses, systemic medicines and inflammatory disease; dry mouth, fatigue and joint symptoms can indicate systemic involvement. [1]
  • Perform a comprehensive eye evaluation with tear-film and ocular-surface assessment, particularly before cataract or refractive surgery. External examination and slit-lamp biomicroscopy assess tear quality, quantity and stability and help identify alternative causes of irritation. [1]
  • Distinguish aqueous tear deficiency from evaporative disease while recognizing their frequent coexistence. Assess severity with symptoms and signs together; mild, moderate and severe categories overlap and should not replace individualized assessment. [1]
  • Use tear break-up time, ocular-surface staining and other tests in clinical context. Schirmer results vary and must not be the sole diagnostic criterion. A matrix metalloproteinase test may support assessment of inflammation but does not distinguish dry eye from other inflammatory ocular-surface diseases. [1]
  • Consider laboratory and clinical autoimmune evaluation when significant dry eye accompanies autoimmune symptoms, such as dry mouth, or a family history. Suspected Sjögren syndrome warrants serological assessment; patients with Sjögren syndrome should be comanaged with a rheumatologist. [1]

Treat contributors and escalate according to response

  • Explain the chronic nature of dry eye and agree realistic goals. Treat modifiable causative factors alongside tear replacement, which is often unsuccessful when used alone without addressing those contributors. [1]
  • For symptoms suggestive of mild dry eye without signs, a trial of artificial tears is appropriate after excluding other causes of irritation. Address aggravating medicines, smoke exposure, drafts and low humidity; screen breaks and conscious complete blinking may help. [1]
  • Select lubricants according to the patient’s needs and ability to instil them. Thicker gels or ointments last longer but can blur vision. When substitutes are used frequently and chronically, for example more than four times daily, nonpreserved products are generally recommended. [1]
  • Treat contributing blepharitis or meibomitis and correct clinically relevant eyelid abnormalities. The initial staged options include eyelid hygiene and warm compresses, with lipid-containing lubricants considered when meibomian gland dysfunction is present. [1]
  • If initial care is inadequate, select additional treatments by presentation and evidence. Options include nonpreserved lubricants, overnight ointment or moisture chambers, gland heating/expression and prescription anti-inflammatory or tear-stimulating treatments; choices within a stage are not ranked. [1]
  • For moderate dry eye, anti-inflammatory treatment may be added to aqueous enhancement. Cyclosporine and lifitegrast are options, but the source does not establish one approved treatment as superior through direct prospective head-to-head comparison. [1]
  • Use low-dose topical corticosteroids at infrequent intervals for short courses to suppress ocular-surface inflammation when appropriate. Monitor patients receiving them for increased intraocular pressure and cataract formation. [1]
  • Do not present oral fatty-acid supplements as reliably effective dry-eye treatment. The source reports no benefit over placebo in a large masked trial of moderate-to-severe disease, despite some supportive reports in blepharitis and limitations from variable formulations. [1]
  • In aqueous tear deficiency, consider punctal occlusion when medical aqueous enhancement is ineffective or impractical; plugs are best used after tear homeostasis is achieved. Discuss irritation, epiphora and possible obstruction or infection rather than treating plugs as universally benign. [1]

Manage refractory disease and arrange follow-up

  • Before permanent punctal cautery, generally trial removable occlusion to assess epiphora. A stepwise approach usually cauterizes no more than one punctum in each eye per session; limited tarsorrhaphy is an option for severe disease unresponsive to other therapies. [1]
  • For severe refractory dry eye, specialist options include serum-derived drops and therapeutic lenses. Scleral-lens use depends on fit, cost and ability to handle lenses; soft lenses carry additional infection risk, especially with extended wear or associated neurotrophic keratopathy. [1]
  • Tailor follow-up to severity, treatment and response, reassessing symptoms, ocular-surface damage and understanding of therapy. Sterile corneal ulceration associated with dry eye may require daily review. [1]
  • Arrange ophthalmologist evaluation for moderate or severe pain, failure of treatment, corneal infiltration or ulceration, progressive conjunctival scarring or vision loss. Treatment-resistant moderate-to-severe disease or suspected systemic disease merits timely specialist referral. [1]
  • Evaluate and manage dry eye before and after lens-based surgery. Explain that refractive surgery may worsen symptoms; achieve effective dry-eye treatment first, because uncontrolled dry eye is a contraindication to keratorefractive surgery. [1]
  • Consider a neuropathic pain contribution when symptoms exceed observed signs or persist despite appropriate treatment and resolution of surface abnormalities. First assess the ocular surface thoroughly; neuropathic ocular pain may need coordinated ophthalmology, pain, neurology and mental-health care. [1]

Limitations and use

  • This is a selected summary of the AAO source approved in September 2023. It is not a complete medication prescribing guide, paediatric protocol or Sjögren classification algorithm.
  • The source gives inconsistent lifitegrast concentrations in its highlights and detailed narrative; this summary therefore does not supply a lifitegrast concentration or dosing regimen. Confirm product-specific prescribing information.
  • Staged treatments are options rather than an obligatory sequence or proof of equivalent efficacy. Detailed systemic secretagogue, neuropathic-pain and surgical protocols are outside this summary.

This summary is selective and does not reproduce every recommendation. Apply the source’s population, setting and eligibility criteria, together with clinical judgement and local policy.

Summary sources

  1. 1
    Dry eye syndrome

    Selected recommendation material consulted

Preferred Practice Pattern guideline

Publication details

Issuing organisation
AAO
First published
12 February 2024
Resource type
Preferred Practice Pattern guideline · House clinical summary

The source check confirms publication details and the linked edition. It does not certify every recommendation or its suitability for an individual patient. Publisher access conditions may apply.

On this page

  • Scope
  • Establish the diagnosis and contributing mechanisms
  • Treat contributors and escalate according to response
  • Manage refractory disease and arrange follow-up
  • Limitations and use
  • Summary sources
  • Publication details
House
Clinical AIRoundsGuidelinesCalculatorsPricingBlogAboutEditorial policyPrivacyTermsLog in ↗
Clinical intelligence, for physicians.© 2026 House